Biomedicines (Jul 2024)

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases

  • Katarzyna Antosz,
  • Joanna Batko,
  • Marta Błażejewska,
  • Antoni Gawor,
  • Jakub Sleziak,
  • Krzysztof Gomułka

DOI
https://doi.org/10.3390/biomedicines12071531
Journal volume & issue
Vol. 12, no. 7
p. 1531

Abstract

Read online

Interleukin-5 functions as a B-cell differentiation factor, but more importantly, in the context of this review, it plays a variety of roles in eosinophil biology, including eosinophil differentiation and maturation in the bone marrow, and facilitates eosinophil migration to tissue sites, usually in the context of an allergic reaction. Given the availability of selective anti-IL-5 drugs such as mepolizumab and reslizumab, as well as the IL-5 receptor antagonist benralizumab, it is worth investigating whether they could be used in some cases of allergic disease. Asthma has a well-documented involvement of IL-5 in its pathophysiology and has clear benefits in the case of anti-IL-5 therapy; therefore, current knowledge is presented to provide a reference point for the study of less-described diseases such as atopic dermatitis, chronic rhinosinusitis, chronic spontaneous urticaria, and its association with both IL-5 and anti-IL-5 treatment options. We then review the current literature on these diseases, explain where appropriate potential reasons why anti-IL-5 treatments are ineffective, and then point out possible future directions for further research.

Keywords